January 1, 2004Thrombosis and Haemostasis
Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke
Key result
The prothrombin G20210A mutation (OR 3.75; 95% CI 1.05-13.34) and oral contraceptive use (OR 3.59; 95% CI 1.28-10.5) were significant risk factors for cryptogenic stroke in young adults.
Why the study?
Do Factor V Leiden, prothrombin G20210A mutations, or oral contraceptive use increase the risk of cryptogenic ischemic stroke in young adults?
Population
49 patients under 50 years of age with cryptogenic ischemic stroke, and controls (Mediterranean population)
Comparison
Presence of Factor V Leiden mutation… vs Controls without these mutations or oral…
Design
Case-control
Authors
Discussion
Loading...
Member takes
Implication
May support PT 20210 testing in young cryptogenic stroke; leaves open prospective validation before practice change.
Study Design
Type
Case-Control
Structured PICO
Do Factor V Leiden, prothrombin G20210A mutations, or oral contraceptive use increase the risk of cryptogenic ischemic stroke in young adults?
P
Population
Young adults under 50 years of age with cryptogenic ischemic stroke compared with controls to assess genetic thrombophilic risk factors.
E
Exposure
Presence of Factor V Leiden (FVL) mutation, prothrombin G20210A (PT 20210) mutation, or oral contraceptive (OC) use
C
Comparator
Controls without these mutations or oral contraceptive use
O
Outcome
Cryptogenic ischemic strokehard clinical
Main Result
Odds Ratio: 3.75 (95% CI 1.05–13.34)
Cite This Study
Mira et al. (2004) conducted a case-control in cryptogenic ischemic stroke. Prothrombin G20210A (PT 20210) mutation vs. Controls without the mutation was evaluated on cryptogenic stroke (OR 3.75, 95% CI 1.05-13.34). The prothrombin G20210A mutation (OR 3.75; 95% CI 1.05-13.34) and oral contraceptive use (OR 3.59; 95% CI 1.28-10.5) were significant risk factors for cryptogenic stroke in young adults.